BORIANI, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 91.095
AS - Asia 31.375
EU - Europa 29.450
SA - Sud America 6.799
AF - Africa 575
OC - Oceania 350
Continente sconosciuto - Info sul continente non disponibili 62
Totale 159.706
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 89.934
GB - Regno Unito 10.812
CN - Cina 9.704
SG - Singapore 9.574
BR - Brasile 5.867
HK - Hong Kong 5.834
IT - Italia 5.371
DE - Germania 3.114
SE - Svezia 2.731
TR - Turchia 2.013
UA - Ucraina 1.821
RU - Federazione Russa 1.628
VN - Vietnam 1.074
BG - Bulgaria 866
KR - Corea 711
FI - Finlandia 662
FR - Francia 628
ID - Indonesia 520
BZ - Belize 402
NL - Olanda 375
CA - Canada 336
AR - Argentina 333
AU - Australia 330
IN - India 315
JP - Giappone 283
MX - Messico 246
IE - Irlanda 231
AT - Austria 226
PL - Polonia 221
BD - Bangladesh 215
IQ - Iraq 196
ES - Italia 190
ZA - Sudafrica 154
EC - Ecuador 130
CO - Colombia 118
PK - Pakistan 111
MA - Marocco 106
UZ - Uzbekistan 104
VE - Venezuela 99
LT - Lituania 98
BE - Belgio 79
CL - Cile 69
MY - Malesia 59
JO - Giordania 58
KE - Kenya 58
EG - Egitto 56
RO - Romania 56
PY - Paraguay 55
AZ - Azerbaigian 53
TN - Tunisia 53
CH - Svizzera 52
IL - Israele 52
AE - Emirati Arabi Uniti 50
SA - Arabia Saudita 47
NP - Nepal 45
IR - Iran 44
PE - Perù 44
UY - Uruguay 43
BO - Bolivia 39
GE - Georgia 39
DZ - Algeria 37
EU - Europa 36
JM - Giamaica 36
GR - Grecia 35
TW - Taiwan 35
KZ - Kazakistan 34
PH - Filippine 31
RS - Serbia 31
CZ - Repubblica Ceca 30
DO - Repubblica Dominicana 27
PT - Portogallo 23
HU - Ungheria 22
SN - Senegal 22
TH - Thailandia 22
AL - Albania 21
KG - Kirghizistan 21
PA - Panama 21
BY - Bielorussia 19
DK - Danimarca 19
OM - Oman 19
CR - Costa Rica 17
NZ - Nuova Zelanda 16
LB - Libano 15
PS - Palestinian Territory 15
TT - Trinidad e Tobago 15
NO - Norvegia 14
CU - Cuba 13
SK - Slovacchia (Repubblica Slovacca) 13
AM - Armenia 11
ET - Etiopia 11
GT - Guatemala 11
BH - Bahrain 10
HN - Honduras 10
NG - Nigeria 10
NI - Nicaragua 10
QA - Qatar 10
XK - ???statistics.table.value.countryCode.XK??? 10
A2 - ???statistics.table.value.countryCode.A2??? 9
BA - Bosnia-Erzegovina 9
KH - Cambogia 9
Totale 159.513
Salva come PNG Salva come JPEG
Città #
Fairfield 12.851
Woodbridge 7.524
Southend 7.258
Santa Clara 7.131
Ashburn 7.076
Singapore 6.211
Houston 5.879
Hong Kong 5.775
Seattle 4.983
Cambridge 4.155
Chandler 4.145
Wilmington 4.141
Jacksonville 3.649
Hefei 3.256
Ann Arbor 2.815
London 2.559
Dearborn 2.335
Beijing 1.791
Modena 1.489
Nyköping 1.463
New York 1.390
San Diego 1.252
Izmir 1.221
Los Angeles 912
Princeton 893
Sofia 858
San Jose 857
Chicago 836
The Dalles 823
Eugene 729
Seoul 695
Dallas 645
Moscow 522
Buffalo 515
Jakarta 459
São Paulo 447
Shanghai 428
Belize City 400
Council Bluffs 399
Columbus 394
Milan 377
Ho Chi Minh City 368
Helsinki 358
Munich 269
Bologna 263
Falls Church 257
Rome 257
Hanoi 236
Salt Lake City 234
Boardman 229
Dublin 207
Rio de Janeiro 197
Nuremberg 193
Redondo Beach 189
Atlanta 187
Fremont 187
Tokyo 182
Saint Louis 169
Perth 168
Norwalk 163
Guangzhou 157
Las Vegas 156
Amsterdam 151
Kent 150
Belo Horizonte 141
Albuquerque 135
Kunming 128
Redwood City 120
Lappeenranta 118
Nanjing 117
Toronto 109
Elk Grove Village 104
Frankfurt am Main 103
Brasília 101
Kilburn 100
Warsaw 99
Johannesburg 95
Curitiba 93
Tashkent 93
Brooklyn 92
Tampa 92
Vienna 87
Naples 82
Jinan 80
Phoenix 77
Grafing 75
Mexico City 75
Porto Alegre 74
Florence 72
Baghdad 71
San Francisco 70
Stockholm 69
Sydney 66
Turku 64
Philadelphia 62
Campinas 61
Chiswick 61
Buenos Aires 60
Ribeirão Preto 60
Montreal 59
Totale 119.630
Salva come PNG Salva come JPEG
Nome #
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation 621
La sindrome da pacemaker. 477
Atrial Fibrillation in the Setting of Acute Pneumonia: Not a Secondary Arrhythmia 437
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (Eur Heart J (2021) 42 (373–498) DOI: 10.1093/eurheartj/ehaa612) 430
Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder. Update 2011. 411
Screening for atrial fibrillation: A Report of the AF-SCREEN International Collaboration 408
Registro Italiano Pacemaker e Defibrillatori: Bollettino Periodico 2016 Associazione Italiana di Aritmologia e Cardiostimolazione 361
The future of continuing medical education: the roles of medical professional societies and the health care industry: Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology 319
2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS 316
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial 311
Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca 310
Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol 306
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) 304
Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients 299
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 285
Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care 285
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) 284
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 282
QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study 282
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) 282
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion 280
Clinically guided pacemaker choice and setting: pacemaker expert programming study 277
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 277
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing 275
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 274
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. 273
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis 271
12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility 270
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report 268
Radar-Based Monitoring of Vital Signs: A Tutorial Overview 267
Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing) 266
Implantable cardioverter-defibrillator–computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study 265
Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital) 261
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation 261
'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase 259
The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden 257
The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary 257
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes 254
Heart failure after myocardial revascularization: Risk markers 252
Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial 250
Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples 250
The wearable cardioverter-defibrillator: Current technology and evolving indications 250
New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes 250
The QRS interval in patients treated with resynchronization therapy: which value? 248
Health economics and the European Heart Rhythm Association. 248
Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry 247
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. 246
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 246
Letter by Gasparini and Boriani Regarding Article, "Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)" 245
Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress 245
Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry 244
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 243
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden 243
QRS interval time-related changes and prognosis in heart failure 240
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF 240
Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 240
Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations 240
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 239
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 239
EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation 238
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation [4] 237
Far-field R wave oversensing in dual-chamber pacemakers designed for atrial arrhythmia management: effect of pacing site and lead tip to ring distance 236
Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD 236
Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators 236
Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation 236
European Society of Cardiology-Proposed Diagnostic Echocardiographic Algorithm in Elective Patients with Clinical Suspicion of Infective Endocarditis: Diagnostic Yield and Prognostic Implications in Clinical Practice 236
Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease 236
Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry 235
Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA 233
Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator 233
Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis 233
The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring 232
Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device 232
Prediction of cardiac resynchronization therapy response: value of calibrated integrated backscatter imaging. 231
11C-mHED for PET / CT: principles of synthesis, methodology and first clinical applications 231
Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry 231
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy 230
Biventricular vs. left univentricular pacing in heart failure: Rationale, design, and endpoints of the B-LEFT HF study 230
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial 230
Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance. 230
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope 230
Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review 229
Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection 229
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy 228
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. 228
Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: The VALID-CRT risk score 228
Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry 226
Decrease in patient radiation exposure by a tantalum filter during electrophysiological procedures. 225
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. 225
'Real-World' antithrombotic treatment in atrial fibrillation: The eorp-af pilot survey 225
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 225
Cardiac resynchronization therapy: is systole all that matters? 224
Cardiac resynchronization therapy: effects on left and right ventricular ejection fraction during exercise. 224
Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications 224
Role of ventricular Autocapture function in increasing longevity of DDDR pacemakers: a prospective study. 224
Atrial evoked response integral for automatic capture verification in atrial pacing 224
Remote Monitoring of Patients with an Implanted Device and Patients' Outcomes: The Potential for "Win-Win" Dynamics. 223
Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action 223
Asymptomatic lone atrial fibrillation - how can we detect the arrhythmia? 222
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. 222
Totale 26.377
Salva come PNG Salva come JPEG
Categoria #
all - tutte 719.575
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 719.575
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112.514 0 0 0 0 0 1.348 2.848 2.882 1.051 2.005 1.309 1.071
2021/202215.465 664 1.848 1.677 712 427 1.286 887 786 1.655 1.369 2.411 1.743
2022/202311.536 1.660 974 714 826 1.469 1.536 259 1.187 1.758 206 597 350
2023/20249.853 393 632 435 803 2.283 1.440 447 1.696 223 253 327 921
2024/202533.713 1.151 386 730 1.788 4.911 5.146 3.766 2.148 4.150 2.542 3.045 3.950
2025/202622.582 3.554 1.887 5.259 4.816 5.394 1.672 0 0 0 0 0 0
Totale 162.873